American International Holdings Corp. (OTC: AMIH) reached another milestone. Better still, AMIH announced what many are calling a company-changing catalyst. And while investors may have overlooked its significant announcement as they licked their wounds during a brutal week in the markets, the excellent news is that AMIH's next updates could double up the value, showing that the revenue-generating power of its subsidiary assets is performing as expected, with the intended result to generate substantial increases to shareholder value.
The future looks great, and the “now” is excellent as well. In fact, news last week took the value proposition in AMIH from outstanding to compelling after they announced that its EPIQ MD launched its Commercial Division to target new revenue-generating opportunities from small and medium-sized businesses (SMB's). Not only that, it's finding space within municipalities in its coverage areas, including those in Alaska, Georgia, Illinois, and Texas. Collectively, that launch puts roughly 950,000 entities in AMIH's crosshairs that need affordable, reliable, and attainable healthcare services for their workers.
Creating A Revenue-Generating Juggernaut
For AMIH, the rapid adoption of its platform by a needy market would be a massive win and put into motion its plan to create a revenue-generating juggernaut within the next two years. Even better, milestones met along the way generate value as well. Thus, there's optimism in the camps of both short and long-term investors.
And there are excellent reasons for investors to feel bullish. Foremost, AMIH targeting the vast potential from the more than 950,000 business entities is in addition to EPIQ MD's mission to bring healthcare solutions to the more than 80 million uninsured and underinsured Americans who have been left behind by surging medical costs.
Perhaps the best part of its commercial launch is that it provides a second means to touch potential clients and is especially useful to small and mid-sized companies wanting to provide comprehensive healthcare alternatives for their workers. The problem, though, is that most simply can't afford even basic group insurance coverage. But, saving them from that dilemma, not only can EPIQ MD fill the gap, it does so by offering comprehensive, seamless, and cost-effective patient services that tap into the power of the digital age.
Better Products Build Shareholder Value
Better still, while providing best-in-class patient services, AMIH isn't lost on the importance of building shareholder value. In that respect, know that EPIQ MD and its other subsidiaries are being designed and implemented into the market in a way that maximizes both services and profits. Keep in mind, too, AMIH is also helping to set the trend showing that digital medicine can be effective and, in most cases, offer the same benefits compared to a personal office visit.
Thus, don't let its ease of use mislead you- EPIQ MD is a technological breakthrough for medical treatment that can generate millions of dollars in monthly subscription revenues. For patients, doctors, and investors, it's a win-win-win proposition.
It's timely as well. In fact, EPIQ MD's relevance in the commercial sector is fully validated. And it comes as global populations reprioritize their lives and pay more attention to the value of a sound mind and body.
Employers are also taking notice, with the last eighteen months showing the importance for businesses to become genuinely concerned with the quality of life, mental health, and general wellness and wellbeing of its employees. And although it took a destructive global pandemic to shed light, sentiment in the retail and services sector has shifted significantly to perpetuate the desperate need for fundamental change in employee care.
Not to put a positive spin on a deadly pandemic, but the good that will come out of the pandemic is that employee value is at the forefront of discussions. And millions of people who previously lacked even basic primary care will have a solution available to fill that void. Moreover, as industries struggle to rebuild their workforce, providing access to a comprehensive primary care service like EPIQ MD could be the difference between running one or multiple production shifts. It really is that dramatic. Employees, both current and former, are demanding more for their services. And companies may have to deliver to survive.
EPIQ MD In The Right Market At The Right Time
Best of all, from an investor's perspective, AMIH is in the right market at the right time to capitalize on its massive revenue-generating opportunities. Even better, they are hitting potential clients at the beginning of a changing landscape, where employee health issues are getting more than newfound attention; they are getting priority review. And it's not only the large industrial companies taking notice. Small companies with as little as five workers understand the same value proposition. Hence, the playing field for business is wide open. AMIH is on a mission to meet demand head-on.
And they should do well from having much to offer. EPIQ MD's service options include Primary Care, Mental Health, Life Coaching, Prescription Discount Programs, and Ask-a-Medical-Expert. Better yet, employers can opt for customized branded solutions, create specialized services with a heavy focus in a specific area such as mental health, or create access to solutions for chronic disease management. Thus, AMIH's program is not a one-size-fits-all. And that's a significant advantage.
More importantly, people need what AMIH can offer. A 2018 report indicated that 50% of individuals with employer-sponsored insurance say they have declined or postponed getting healthcare and prescription drugs because of cost. EPIQ MD believes it can change that dynamic by offering a compelling service and changing the quality of life for its users. Best of all, employers can utilize AMIH's platform to get around the rising cost of basic services and, at the same time, alleviate much of the stress their employees have from not having health coverage.
Does it work? Absolutely. And does it save money? For sure. According to a case study by Forrester Research, that company increased productivity by 14% and saved over $6 million in healthcare costs over three years. That's a single company. And it wasn't an extreme example. Millions of companies can benefit from similar percentages. And while the numbers vary, at the end of the day, businesses and their employees are winners.
AMIH In Hyper-Growth Mode
For investors wanting growth, this is important as well. The company has made clear that EPIQ MD is only the tip of the spear for the AMIH strategy of creating a portfolio of synergistic entities. Moreover, a detailed look at EPIQ MD reveals that its consumer-targeted program's multiple touchpoints across the healthcare supply chain can be the most comprehensive and affordable alternative to the traditional high-cost insurance-based healthcare in the market.
Best of all, guidance from AMIH has always been spot on. Hence, believe it when they say the EPIQ MD experience can be a game-changer in the sector.
Results are already proving that value. But don't trust the share price as a barometer of success. Use that as an opportunity indicator. And it is indicating that the investment proposition in AMIH is better than ever. Moreover, with actions taken in the past two quarters to create, develop, and launch its newest products, that needle should be pointing decidedly toward a bullish opportunity.
Remember, too, AMIH isn't a pure medical services play. It has a tremendous intrinsic value from being positioned to capitalize on the massive opportunities created by the digital revolution in healthcare. No longer are digital services part of a revolution; it's the norm. Everything from checking in, billing, patient visits, and test results is provided digitally. And for those that don't understand how to use the technology, they better learn. Practices will further implement digital technology as healthcare providers and offices get squeezed by tight margins and labor shortages. As a result, practices across the country are turning digital to lessen overhead and reduce redundant costs. Thus, this landscape is changing faster than most ever expected.
Still, it's a change in the landscape that AMIH intends to monetize. And they are doing so now after reprioritizing its business strategy to focus on substantial market and services opportunities exposed by the COVID-19 pandemic. They are also turning challenges into opportunities.
Assets Targeting A $4.2 Trillion Market
In-play is a company on a fast track to maximizing its revenue-generating potential from the $4.2 trillion US health care industry. Thus, it's a good time to look forward to what this undervalued company has to offer.
Two programs at AMIH are actively working to capitalize on what AMIH thinks is the low-hanging fruit of opportunity. First is through ZipDoctor, a capital-efficient, digitally-based platform that affordably connects people and small businesses with healthcare practitioners. The sector is already hot; AMIH is tapping into it.
By the end of this year, telemedicine will have become a more than $194 billion industry. And ZipDoctor wants a piece. Better yet, they think they can earn a sizable share of the market after market-testing results led to AMIH building and launching EPIQ MD, which, as noted, the company believes represents the next generation in telehealth and wellness. From its data, it's also designed to be more niche-focused.
Unlike mainstream companies like Teledoc that contract directly with health insurers to reduce their costs of providing primary care to their insureds, EPIQ MD targets a "massive niche" by reaching out to more than 80 million US residents who are either under-insured or have no insurance at all. Try using Teledoc without insurance. It won't happen.
Moreover, AMIH has found through its own research that many of its target consumers, including small businesses that want to offer provider services, are willing to pay more for a comprehensive suite of wellness services. However, "more" isn't a whole lot when working with EPIQ MD.
In fact, monthly subscription rates start as low as $29.95, and with that comes access to primary care physicians, mental health professionals, nutritional counseling, and deeply discounted rates to select third-party providers of prescriptions, in-person diagnostic, and lab services. Compare that to an insurance premium, and it's almost pennies on the dollar.
The better news is that market growth, even staggered, equates to value. And with its flagship portfolio asset EPIQ MD now penetrating initial targeted markets and further complemented with a commercial product offering, updates on expansion and revenue-generating catalysts may be near. Hence, watch that investment indicator along with the headlines. Both are set up for bullish deliveries.
The more excellent news is that there's more to like.
LifeGuru Targets A Much-Needed Mental health Market
A second value driver will come through LifeGuru, a life coaching platform that connects people with specialized life coaches with expertise mentoring people through life's challenges. Not only stress, either. LifeGuru services expect to touch people to counsel romance, finance, career, health, and family issues. It's a platform that grew out of the challenges presented by COVID-19, which of course, wreaked havoc on the personal lives of more than 320 million Americans. And it still is.
Still, despite headlines saying things are getting better, tens of millions of people continue to be impacted. As it did with ZipDoctor and EPIQ MD, AMIH seized its opportunity to develop a platform to help coaches access new clients nationwide and match people nationwide with their optimal life coach. Better still, like its sister programs, LifeGuru targets a multi-billion-dollar sector opportunity. Similarly, they also make the program accessible and affordable.
The current business plan calls for coaches to pay a subscription fee for access to the platform and for clients to pay an affordable rate for tele-sessions. The value to AMIH comes through receiving recurring revenue for building, marketing, and managing the platform. While still a non-revenue-generating asset, AMIH is taking steps to monetize this platform sooner rather than later. Better yet, they are creating the LifeGuru platform to be globally accessible and offered in multiple languages.
Thus, like EPIQ MD, news about this innovative services platform can be a value driver in the coming months. AMIH is expected to provide updates about coach recruitment and plans to begin marketing programs as early as this year. So, while 2021 has been a busy year, expect 2022 to be substantially more productive on the revenues side of the business. Still, there's plenty more in the development pipeline to ensure the company maintains its trajectory set to higher valuations.
The most excellent news is that its mission to create and enhance shareholder value is well underway. And that makes its current share price more than attractive; it makes it a considerable and actionable investment opportunity.
Creating The Platforms That Drive Growth
The bottom line is clear- AMIH is a company in motion. Moreover, they are far from one-dimensional, which will inevitably deliver multiple shots on revenue-generating goals. And while it wasn't highlighted earlier, expect EPIQ Innovations, the sister company to EPIQ MD, to bring a curated assortment of proprietary, in-house formulated advanced nutraceutical products to market. That mission is designed to seize upon a market that exploded in value since COVID-19, with consumers turning toward non-prescription immune-boosting and other nutraceuticals. That initiaitve is a power booster, too.
And, of course, expect growth from both ZipDoctor and EPIQ MD to drive value in the current and coming quarters. Those platforms can turn digital into gold. And they likely will with AMIH getting aggressive in its marketing to make sure potential clients understand the value proposition.
Thus, while shares are churning around the $0.06 level, the action behind the scenes sets the stock up to break higher. For savvy investors, that's usually the best place to find deals, peeking behind the curtains and trading ahead of the pack.
And with several catalysts potentially near term, a new commercial launch of its flagship platform, and a target market of more than 80 million people, the investment proposition in AMIH looks more than compelling; it's timely.
Disclaimers: Shore Thing Media, LLC. (STM, LLC.) is responsible for the production and distribution of this content. STM, Llc. is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by STM, Llc. is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall STM, Llc. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by STM, Llc., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. STM, Llc. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, STM, Llc., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. STM, LLC has been compensated up to twenty-thousand dollars cash via wire transfer by a third party to produce and syndicate content for American International Holdings Group, Inc. for a period of one month. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website by visiting primetimeprofiles.com/disclaimer.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.